⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of AltruBio, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
AltruBio, Inc.
↗San Francisco, USA
AltruBio is a clinical-stage biotechnology company dedicated to developing novel therapeutics for immunological and inflammatory diseases. The company leverages its proprietary immune checkpoint enhancer (ICE) platform, which targets PSGL-1 to selectively downregulate chronically overactivated T-cells, aiming to restore immune balance without systemic suppression.
Its lead candidate, ALTB-268, is a tetravalent PSGL-1 agonist antibody designed for subcutaneous administration. The company is actively advancing its pipeline with a focus on indications such as ulcerative colitis (UC), psoriatic arthritis, and graft-versus-host disease, building upon proof-of-mechanism data established by its first-generation molecule, ALTB-168.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2000
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$225M
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Monoclonal antibody
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Inflammatory Bowel Disease Clinical Advisory Board (includes experts from Medical University of Vienna and other institutions)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Judy Chou - CEO
LINKS
Website:altrubio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AltruBio, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.